Myriad Genetics, Inc. (NASDAQ:MYGN)
|
25.50 +0.25 (0.99%) Mar 16 - Close |
|
|
|
After-Hours 25.25 0.00 (0.00%) Mar 16 15:59ET
- Compare MYGN with:
- View: Line | Candlestick
Company Profile
Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, UT 84108
United States - Map
Phone: (801) 584-3600
Fax: (801) 584-3640
Website: www.myriad.com
State of incorporation: Delaware
CEO: Peter D. Meldrum
Employees: 869
Sector: Healthcare
Industry Group: Drugs
Industry: Diagnostic Substances
We are a leading biopharmaceutical company
A healthcare company, focused on the development and marketing of novel molecular diagnostic products.
Recent news for MYGN
-
InPlay: Myriad genetics expression test, PROLARIS, accurately predicts prostate cancer recurrence
Briefing.com - Mar 08 at 4:06PM (EST)
-
Novel Gene Expression Test, PROLARIS(TM), Accurately Predicts Prostate Cancer Recurrence
GlobeNewswire - Mar 08 at 4:05PM (EST)
-
Forbes.com - Mar 05 at 4:05PM (EST)
-
Coverage initiated on Myriad Genetics by Auriga U.S.A
Briefing.com - Mar 05 at 2:16AM (EST)
-
Motley Fool - Mar 04 at 2:42PM (EST)
-
Motley Fool - Mar 03 at 3:01PM (EST)
-
Myriad Genetics, Inc. (MYGN) President and CEO to Ring the NASDAQ Stock Market Opening Bell
GlobeNewswire - Mar 02 at 11:16AM (EST)
-
Myriad Genetics Launches PROLARIS(TM): First Diagnostic Test to Predict Prostate Cancer Recurrence
GlobeNewswire - Mar 02 at 8:36AM (EST)
-
[video] Health Care Reform or Political Folly?
CNBC - Feb 25 at 11:20AM (EST)
-
GlobeNewswire - Feb 25 at 6:30AM (EST)